• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bio-Path Holdings, Inc. - Common Stock (NQ: BPTH )

    1.260 -0.230 (-15.44%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bio-Path Holdings, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline
    Via Benzinga
    Bio-Path Holdings Shares Were On The Rise: What's Going On?
    Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2... 
    Via Benzinga
    Gold Falls Sharply, Lamb Weston Shares Plunge
    Via Benzinga
    US Stocks Higher, Micron Reports Downbeat Sales
    Via Benzinga
    Uncovering Potential: Bio-Path Holdings's Earnings Preview
    Via Benzinga
    Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
    Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes 
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
    Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
    Via Newsfile
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Bio-Path Holdings Reports Third Quarter 2024 Financial Results
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 15, 2024
    Via Benzinga
    Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Nasdaq Surges Over 1%; DocuSign Shares Spike Higher
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook
    Via Benzinga
    ACHR, BPTH, PLUG, REGRF:
    Leaders Report Latest Advances 
    Via News Direct
    Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
    Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Bio-Path Holdings Announces Publication in Biomedicines
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
    Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
    Via Newsfile
    Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    What Happened With Bio-Path Stock Today?
    Bio-Path shares ended Wednesday's session slightly higher after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A. 
    Via Benzinga
    Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
    From Bio-Path Holdings, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.